Show simple item record

dc.contributor.authorEvans, R
dc.contributor.authorHawkins, N
dc.contributor.authorDequen-O'Byrne, P
dc.contributor.authorMcCrea, C
dc.contributor.authorMuston, D
dc.contributor.authorGresty, C
dc.contributor.authorGhate, SR
dc.contributor.authorFan, L
dc.contributor.authorHettle, R
dc.contributor.authorAbrams, KR
dc.contributor.authorde Bono, J
dc.contributor.authorHussain, M
dc.contributor.authorAgarwal, N
dc.coverage.spatialFrance
dc.date.accessioned2022-09-02T14:56:12Z
dc.date.available2022-09-02T14:56:12Z
dc.date.issued2021-09-03
dc.identifier10.1007/s11523-021-00837-y
dc.identifier.citationTargeted Oncology, 2021, 16 (5), pp. 613 - 623en_US
dc.identifier.issn1776-2596
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5400
dc.identifier.eissn1776-260X
dc.identifier.eissn1776-260X
dc.identifier.doi10.1007/s11523-021-00837-y
dc.description.abstractBACKGROUND: In oncology trials, treatment switching from the comparator to the experimental regimen is often allowed but may lead to underestimating overall survival (OS) of an experimental therapy. OBJECTIVE: This study evaluates the impact of treatment switching from control to olaparib on OS using the final survival data from the PROfound study and compares validated adjustment methods to estimate the magnitude of OS benefit with olaparib. PATIENTS AND METHODS: The primary population from PROfound (Cohort A) was included, alongside two populations approved for treatment with olaparib by the European Medicines Agency and US Food and Drug Administration: BRCAm and Cohort A+B (excluding the PPP2R2A gene). Five methods were explored to adjust for switching: excluding or censoring patients in the control arm who receive subsequent olaparib, Rank Preserving Structural Failure Time Model (RPSFTM), Inverse Probability of Censoring Weights, and Two-Stage Estimation. RESULTS: The RPSFTM was considered the most appropriate approach for PROfound as the results were robust to sensitivity analysis testing of the common treatment effect assumption. For Cohort A, the final OS hazard ratio reduced from 0.69 (95% CI 0.5-0.97) to between 0.42 (0.18-0.90) and 0.52 (0.31-1.00) for olaparib versus control, depending on the RPSFTM selected. Median OS reduced from 14.7 months to between 11.73 and 12.63 months for control. CONCLUSIONS: The magnitude of the statistically significant (P < 0.05) survival benefit of olaparib versus control observed in Cohort A of PROfound is likely to be underestimated if adjustment for treatment switching from control to olaparib is not conducted. The RPSFTM was considered the most plausible method, although further development and validation of robust methods to estimate the magnitude of impact of treatment switching is needed.
dc.formatPrint-Electronic
dc.format.extent613 - 623
dc.languageeng
dc.language.isoengen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofTargeted Oncology
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0en_US
dc.subjectCohort Studies
dc.subjectHumans
dc.subjectMale
dc.subjectProportional Hazards Models
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.subjectRecombinational DNA Repair
dc.subjectTreatment Switching
dc.subjectUnited States
dc.titleExploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).en_US
dc.typeJournal Article
dcterms.dateAccepted2021-08-20
dc.date.updated2022-09-02T14:55:42Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1007/s11523-021-00837-yen_US
rioxxterms.licenseref.startdate2021-09-03
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34478046
pubs.issue5
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume16
icr.researchteamPrCa Targeted Therapyen_US
dc.contributor.icrauthorDe Bono, Johann
icr.provenanceDeposited by Mr Arek Surman on 2022-09-02. Deposit type is initial. No. of files: 1. Files: Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0